Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis, ALS
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04165850
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Amyotrophic Lateral Sclerosis
The Effect of Low-İntensity Combined Exercises in Patients With Early Stage ALS.
The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS.
- Trial name
- NCT05716074
- Testing
- Supervised exercise, Home exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Amyotrophic Lateral Sclerosis, ALS
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps.
- Trial name
- NCT01363401
- Testing
- HYNR-CS inj, Control group
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Corestemchemon, Inc.
Spinobulbar Muscular Atrophy, Kennedy's Disease
Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
This is a therapeutic trial study to demonstrate whether Goserelin, a LHRH agonist has benefit in SBMA Objective: 1. To study effects of Goserelin to clinical course of patients with spinal and bulbar muscular atrophy in Thailand…
- Trial name
- NCT00851461
- Testing
- Goserelin, Electrophysiologic study, tissue biopsy
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Ramathibodi Hospital
Amyotrophic Lateral Sclerosis
Reinnervation and Neuromuscular Transmission in ALS
The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis: 1.
- Trial name
- RANTAL (NCT06219759)
- Testing
- Observational study
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Motor Neuron Disease, Pneumonia
Respiratory Complications in ALS
Respiratory failure is the leading cause of death in motor neuron disease (MND) patients. Symptoms of respiratory dysfunction in MND patients include sleep disturbance, excessive daytime somnolence, morning headaches and…
- Trial name
- NCT04430686
- Testing
- Questionaires
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Ultra-high-caloric, Fatty Diet in ALS
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIPCAL-ALS II (NCT06280079)
- Testing
- Ultra-high-caloric fatty diet
- Where
- 23 sites in Germany
- Volunteers
- 399 people
- Sponsor
- University of Ulm
Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment.
- Trial name
- SpeechBCI (NCT07698496)
- Testing
- Chronic speech BCI
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
ALS (Amyotrophic Lateral Sclerosis)
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality.
- Trial name
- NCT07321860
- Testing
- Galunisertib + Nerandomilast Combination
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gipfel Life Sciences GmbH
Muscular Atrophy, Spinal, Ultrasound
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
Intrathecal administration of Nusinersen, an antisense oligonucleotide capable of increasing Survival Motor Neuron protein production, has been tested in Spinal Muscular Atrophy (SMA) to improve motor function and survival.
- Trial name
- NCT04674618
- Testing
- US-assisted nusinersen administration
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic
Dual Treatment With Lithium and Valproate in ALS.
This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate and lithium carbonate. After a random assignation of the dual treatment vs.
- Trial name
- NCT03204500
- Testing
- Active treatment with dual therapy
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Amyotrophic Lateral Sclerosis
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- NCT00035815
- Testing
- Insulin like growth factor, type 1
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent…
- Trial name
- NCT03321487
- Testing
- Blood-Brain Barrier opening with MRgFUS
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
TRIAL READY (Clinical Trial Readiness)
This study, being conducted under the auspice of the CReATe Consortium, will enroll patients with ALS and related disorders as well as healthy controls, with the goal of facilitating clinical validation of leading…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis
- Trial name
- NCT03912987
- Where
- 3 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- University of Miami
Amyotrophic Lateral Sclerosis, ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support.
- Trial name
- NCT03324399
- Testing
- probiotic
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Amyotrophic Lateral Sclerosis, Muscular Dystrophy
Innovative Ultrasound Technology in Neuromuscular Disease
This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine…
- Conditions
- Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Radiculopathy, Myopathy
- Trial name
- AQUIRe (NCT02104921)
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Spinal Muscular Atrophy
Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States
This global, retrospective, non-interventional, medical chart review (MCR), descriptive study collected patient-level data in regions outside the US.
- Trial name
- NCT06178393
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
ALSFTD, ALS (Amyotrophic Lateral Sclerosis)
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants…
- Conditions
- ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
- Trial name
- PROBIOTIC (NCT06051123)
- Testing
- Probiotic
- Where
- 3 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.